Q3 EPS Estimate for Palvella Therapeutics Cut by Analyst

Key Points

• HC Wainwright lowered Palvella Therapeutics’ Q3 2026 EPS estimate to a loss of $1.98 per share from $1.69, while maintaining a Buy rating and a $270 price target.
• Palvella recently reported a quarterly loss of $1.52 per share, missing the consensus estimate of a $1.17 loss by $0.35. Despite mixed analyst opinions, the stock carries a consensus Buy rating and an average target price of $209.14.
• Shares opened at $154.93, near their 52-week high of $161.38, with a $2.23 billion market capitalization; institutional investors own 40.11% of the company, while insiders own 17.20%.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Equities researchers at HC Wainwright cut their Q3 2026 earnings estimates for Palvella Therapeutics in a report released on Wednesday, August 5th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($1.98) for the quarter, down from their previous forecast of ($1.69). HC Wainwright has a "Buy" rating and a $270.00 price objective on the stock. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($5.58) per share. HC Wainwright also issued estimates for Palvella Therapeutics' Q4 2026 earnings at ($2.05) EPS, FY2026 earnings at ($6.79) EPS, FY2027 earnings at ($7.43) EPS, FY2028 earnings at ($0.83) EPS, FY2029 earnings at $6.18 EPS and FY2030 earnings at $19.10 EPS.

Several other research analysts have also issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Stephens reissued an "overweight" rating and issued a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Chardan Capital upgraded Palvella Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a report on Wednesday. Finally, Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Palvella Therapeutics has a consensus rating of "Buy" and an average target price of $209.14.

Palvella Therapeutics Price Performance

Palvella Therapeutics stock opened at $154.93 on Friday. Palvella Therapeutics has a 1-year low of $37.33 and a 1-year high of $161.38. The business has a fifty day moving average price of $132.97 and a 200-day moving average price of $119.75. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -32.08 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35).

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV acquired a new stake in shares of Palvella Therapeutics in the first quarter worth $28,000. Group One Trading LLC boosted its holdings in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company's stock valued at $35,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics in the third quarter valued at $36,000. JPMorgan Chase & Co. grew its position in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock worth $73,000 after purchasing an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Palvella Therapeutics during the 2nd quarter worth about $85,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company's stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source